-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: With the ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the world has ushered in another year of global health emergencies
.
Extensive research over the past year has shown that older patients and those with pre-existing conditions such as obesity, diabetes and cancer are more likely to contract SARS-CoV-2 and develop life-threatening pneumonia
The world has ushered in another year of global health emergency as the 2019 coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), persists
Patients with hematological cancers had a higher case fatality rate (CFR) compared with patients with solid cancers (37% vs.
OBJECTIVE: Cancer patients have an increased risk of coronavirus disease 2019 (COVID-19) and reduced responses to various vaccines
.
This meta-analysis aimed to assess the serological response to COVID-19 vaccination in cancer patients
METHODS: Electronic databases were systematically searched on 1 August 2021 for studies reporting serologic responses to COVID-19 vaccines in cancer patients
.
A random-effects model was used to achieve pooled serological response rates and odds ratios (ORs)
Results: We analyzed 16 observational studies with a total of 1453 cancer patients
.
Most studies used mRNA vaccines (BNT162b2 or mRNA-1273)
Figure 1 Meta-analysis of serological responses after one dose of vaccine
.
B Meta-analysis of serological responses after two doses of vaccineFigure 1 Meta-analysis of serological responses after one dose of vaccine
Figure 2.
Meta-analysis of serological responses after one dose of vaccine compared with controls
.
B Meta-analysis of serological responses after two doses of vaccine compared with controlsFigure 2.
Cancer patients, especially those with hematological B-cell malignancies, have low serological responses to the COVID-19 vaccine
Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis.
Leave a comment here